

PASTAN and CHOWDHURY
Application No.: 09/581,345
Page 2

PATENT

IN THE CLAIMS

Please **cancel** claim 122.

Please **amend** the claims as follows:

Sub E1
Anti-mesothelin
113. (Amended) An isolated antibody comprising a variable heavy (V_H) chain and a variable light (" V_L ") chain, which V_H and V_L chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

114. (Amended) An antibody of claim 113, wherein said V_H and V_L chains comprise framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).

115. (Amended) An antibody of claim 113, wherein said antibody is a single chain Fv ("scFv").

D2
117. (Amended) An antibody of claim 116, wherein said peptide linker has the sequence of SEQ ID NO:6.

US
118. (Amended) An scFv of claim 115, wherein said scFv has the sequence shown in Figure 1 (SEQ ID NO:5).

5747654
As set forth in patent
D3
120. (Amended) A dsFv of claim 119, having a V_L chain containing a cysteine at position 42, 43, 44, 45, 46, 98, 99, 100, or 101, such positions being determined in accordance with the numbering scheme published by Kabat and Wu, and a V_H chain containing a cysteine at position 43, 44, 45, 46, 47, 103, 104, 105 or 106, such positions being determined in accordance with the numbering scheme published by Kabat and Wu.

121. (Amended) An antibody of claim 113, wherein said V_H and V_L chains are encoded by SEQ ID NO:1.

PASTAN and CHOWDHURY
Application No.: 09/581,345
Page 3

PATENT

SUB
E2
135. (Amended) An isolated antibody comprising a variable heavy ("V_H") chain which V_H chain has complementarity-determining regions as set forth in Figure 1 (SEQ ID NO:5).
anti-mesothelin

136. (Amended) An antibody of claim 135, wherein said V_H chain has the sequence set forth in Figure 1 (SEQ ID NO:5).

SUB
E3
140. (Amended) An isolated antibody comprising a variable light ("V_L") chain which V_L chain has complementarity-determining regions as set forth in Figure 1 (SEQ ID NO:5).
anti-mesothelin

141. (Amended) An antibody of claim 140, wherein said V_L chain has the sequence set forth in Figure 1 (SEQ ID NO:5).

145. (Amended) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable heavy ("V_H") chain and a variable light ("V_L") chain, which V_H and V_L chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

146. (Amended) A composition of claim 145, wherein said V_H and V_L chains comprise framework regions ("FRs") as shown in Figure 1 (SEQ ID NO:5).

147. (Amended) A composition of claim 145, wherein said antibody is a single chain Fv ("scFv").

149. (Amended) A composition of claim 145, wherein said peptide linker has the sequence of SEQ ID NO:6.

PASTAN and CHOWDHURY
Application No.: 09/581,345
Page 4

PATENT

D7
W

150. (Amended) A composition of claim 147, wherein said scFv has the sequence shown in Figure 1 (SEQ ID NO:5).

D8

154. (Amended) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable heavy ("V_H") chain having complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

155. (Amended) A composition of claim 154, wherein said V_H chain comprises framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).

D9

158. (Amended) A composition comprising a pharmaceutically acceptable carrier and an immunoconjugate which comprises a therapeutic agent or a detectable label attached or fused to an anti-mesothelin antibody comprising a variable light ("V_L") chain having complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5).

159. (Amended) A composition of claim 158, wherein said V_L chain comprises framework regions ("FRs") as set forth in Figure 1 (SEQ ID NO:5).

162. (Amended) A kit for detecting mesothelin on the surface of cells, said kit comprising:

D10

(i) anti-mesothelin antibody comprising a variable heavy (V_H) chain and a variable light ("V_L") chain, which V_H and V_L chains have complementarity-determining regions ("CDRs") as set forth in Figure 1 (SEQ ID NO:5); and,

(ii) instructions printed on a tangible medium, said instructions describing methods of using and said antibody for detecting mesothelin on the surface of cells.